Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MYECO GROUP LTD Interim / Quarterly Report 2011

Feb 15, 2011

65304_rns_2011-02-15_169ea221-a925-4749-8045-d32d5cbe3580.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

==> picture [190 x 120] intentionally omitted <==

TO: COMPANY ANNOUNCEMENTS OFFICE ASX LIMITED DATE: 16[th] February 2010

- MATERIAL DIFFERENCES IN HALF YEAR RESULTS

The Company wishes to inform that it is expecting an improved loss position to its half year results to 31[st] December 2010 (approx loss of $1.2 million) in comparison to the previous corresponding period in 2009 (loss of $3.44 million).

The major items affecting the financial results (based on internal management accounts) for the Half -Year to 31[st] December 2010 are:

Revenue

The Company anticipates consolidated revenue of approximately $1 million for the half year to 2010, comprising Sales of $781,060 and a Research and Development Rebate of $169,442.This revenue is broadly consistent with the consolidated revenue reported in the corresponding period in 2009 of $1,015,471.

Improved Loss Position

The Company anticipates a consolidated loss of approximately $1.2 million for the 6 months to 31st December 2010 compared with a loss of $3,444,775 for the same period in 2009.

The major reasons for the improved loss position for the 6 months to 2010 as compared to the corresponding period in 2009 are:

  • A reduction in the loss of the Company’s operating activities by approximately $0.18 million (to approximately $ 1.27 million) over the loss recorded in the six months to 31 December 2009 of $1,453,905.

  •  As disclosed in the 2010 annual report, Bioglobal Limited ceased to be an “Associate” (as defined in AASB 128) of the Company from 1 July 2010 .As a result, the Company has discontinued to account for its 18.44% investment in Bioglobal Limited using the equity method of accounting (AASB 128) and has accounted for that investment as a financial asset in accordance with AASB139. Accordingly, the cost base of the investment is recorded at the carrying

==> picture [511 x 44] intentionally omitted <==

amount of the investment at the date that it ceased to be an “Associate”. The resultant gain of $736,883 was recorded through the Profit and Loss during the December 2010 half year.

Moreover, in the half year to December 2009, the company recognised a share of Bioglobal Limited loss of $140,359.As the Company has now accounted for its investment in Bioglobal in accordance with AASB-139, recognition of such share of profit or loss of Bioglobal is no longer required.

  •  In the December 2009 half year the Company recorded a provision for impairment of the Company’s Secured Loan to Aquenox Limited of $1,000,000 together with accrued interest of $198,041.No provisions relating to investments are required in the December 2010 half year.

PAT VOLPE Chairman